Pulmonary hypertension combination therapy may lead to greater disease burden

Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding IV PGI2.

Researchers from Massachusetts General Hospital and Novartis Pharma AG in Switzerland performed statistical tests on 446 patients with PAH, of which (a) 337 were receiving monotherapy; (b) 88 were receiving non-IV PGI2 combination therapy; and (c) 21 were receiving IV PGI2 .

Results showed that pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores were highest in those treated with IV PGI2.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

Related Stories

Gene therapy may be effective in treating PAH

date May 19, 2010

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension (PAH), according to researchers at the University of Adelaide in Australia.

Recommended for you

Third Minnesota turkey farm hit by bird flu outbreak

date 17 hours ago

An outbreak of a bird flu strain that's deadly to poultry deepened Saturday when state and federal officials confirmed a third Minnesota turkey farm has been infected, this time in one of the state's top poultry producing ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.